1. Ureadepsipeptides as ClpP Activators
- Author
-
Darcie J. Miller, Miranda J. Wallace, Ying Zhao, LaFleur, William R. Shadrick, Kim Lewis, John M Elmore, Y. Li, Jiuyu Liu, Elizabeth C. Griffith, Rajendra Tangallapally, Martin N. Cheramie, Zhong Zheng, Richard E. Lee, Brian P. Conlon, Lei Yang, Aman P. Singh, and Robin B. Lee
- Subjects
0301 basic medicine ,Staphylococcus aureus ,medicine.medical_treatment ,030106 microbiology ,Enzyme Activators ,medicine.disease_cause ,Article ,03 medical and health sciences ,Bacterial Proteins ,Protein Domains ,Depsipeptides ,medicine ,Urea ,Potency ,Depsipeptide ,Protease ,biology ,Chemistry ,Biofilm ,Endopeptidase Clp ,Metabolism ,biology.organism_classification ,Anti-Bacterial Agents ,030104 developmental biology ,Infectious Diseases ,Biochemistry ,Antibacterial activity ,Bacteria - Abstract
Acyldepsipeptides are a unique class of antibiotics that act via allosterically dysregulated activation of the bacterial caseinolytic protease (ClpP). The ability of ClpP activators to kill nongrowing bacteria represents a new opportunity to combat deep-seated biofilm infections. However, the acyldepsipeptide scaffold is subject to rapid metabolism. Herein, we explore alteration of the potentially metabolically reactive α,β unsaturated acyl chain. Through targeted synthesis, a new class of phenyl urea substituted depsipeptide ClpP activators with improved metabolic stability is described. The ureadepsipeptides are potent activators of Staphylococcus aureus ClpP and show activity against Gram-positive bacteria, including S. aureus biofilms. These studies demonstrate that a phenyl urea motif can successfully mimic the double bond, maintaining potency equivalent to acyldepsipeptides but with decreased metabolic liability. Although removal of the double bond from acyldepsipeptides generally has a significant negative impact on potency, structural studies revealed that the phenyl ureadepsipeptides can retain potency through the formation of a third hydrogen bond between the urea and the key Tyr63 residue in the ClpP activation domain. Ureadepsipeptides represent a new class of ClpP activators with improved drug-like properties, potent antibacterial activity, and the tractability to be further optimized.
- Published
- 2019